美國發炎性腸道疾病治療市場規模、佔有率、趨勢分析報告（按類型、藥物類別、給藥途徑、分銷管道、地區、細分市場預測），2025 年至 2030 年

美國發炎性腸道疾病治療市場的成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，美國發炎性腸道疾病治療市場規模預計到 2030 年將達到 157 億美元，2025 年至 2030 年的複合年成長率為 2.7%。美國潰瘍性大腸炎和克隆氏症盛行率的上升預計將在預測期內推動市場成長。發炎性腸道疾病腸道疾病(IBD) 的發展被認為是受遺傳易感性、免疫系統功能障礙、環境因素、腸道菌叢失衡和生活方式因素等共同影響的。根據 2023 年發表的一篇論文，發炎性腸道疾病疾病是一種相對常見的慢性病，影響超過 0.7% 的美國人，並且在東北地區最為普遍。患者數量的增加需要先進的治療方案，從而推動市場成長。

克隆氏症和結腸炎基金會致力於加強產品開發，以改善發炎性腸道疾病患者的生活品質。基金會已推出專門的融資機制「創投」（Ventures），以支持以產品為導向的研發。

2023年9月，武田宣布FDA已接受該公司提交的生技藥品核准申請(BLA)，用於皮下注射Entyvio（通用名維多珠單抗），用於治療克隆氏症。該監管部門的核准為新藥、生技藥品和醫療設備進入市場鋪平了道路。這有望擴大IBD患者的治療選擇，並改善他們的預後和生活品質。

美國發炎性腸道疾病治療市場報告重點

• 根據類型，克隆氏症在 2024 年佔據了市場主導地位，收入佔有率最大。這一巨大佔有率可以歸因於對更多治療方案和進步的需求，因為克隆氏症是一種影響胃腸道的慢性發炎性疾病，會引起腹痛、腹瀉、體重減輕和疲勞等症狀。
• 根據藥物類別，TNF 抑制劑預計將在 2024 年佔據最大的市場收入佔有率，因為它們能夠有效控制症狀並抑制發炎。
• 根據給藥途徑，注射劑將在 2024 年佔據最大的市場佔有率。注射藥物，例如生技藥品和生物相似藥，旨在針對參與發炎性腸道疾病發炎過程的特定蛋白質和細胞。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國發炎性腸道疾病治療市場變數、趨勢與範圍

• 市場體系展望
• 市場動態
  • 市場促進因素分析
  • 市場限制因素分析
• 商業環境分析
  • 產業分析-波特五力分析
  • PESTLE分析
  • 管道分析
  • 專利到期分析
  • 定價分析

第4章美國發炎性腸道疾病治療市場：按類型分類的業務分析

• 2024 年及 2030 年各類型市場佔有率
• 細分儀表板：按類型
• 2018 年至 2030 年按類型分類的市場規模、預測與趨勢分析
• 克隆氏症
• 潰瘍性大腸炎

第5章美國發炎性腸道疾病治療市場：按藥物類別分類的業務分析

• 2024 年及 2030 年各藥品類別的市場佔有率
• 細分儀表板：依藥物類別
• 2018 年至 2030 年藥品類別市場規模、預測與趨勢分析
• 氨基水楊酸鹽
• 皮質類固醇
• TNF抑制劑
• 白血球介素抑制劑
• 抗整合素
• JAK抑制劑
• 其他

第6章美國發炎性腸道疾病治療市場：依給藥途徑分類的業務分析

• 2024 年和 2030 年按給藥途徑分類的市場佔有率
• 細分儀表板：依給藥途徑
• 2018 年至 2030 年按給藥途徑分類的市場規模、預測和趨勢分析
• 口服
• 注射

第7章美國發炎性腸道疾病治療市場：通路業務分析

• 2024 年和 2030 年按分銷管道分類的市場佔有率
• 細分儀表板：按分銷管道
• 2018 年至 2030 年分銷通路市場規模、預測與趨勢分析
• 醫院藥房
• 零售藥局
• 網路藥局

第8章美國發炎性腸道疾病治療市場：按地區分類的估計和趨勢分析

• 2024 年及 2030 年各地區市場佔有率分析
• 市場儀表板：按地區
• 2018-2030年各地區市場規模及預測趨勢分析
• 西
  • 主要地區趨勢
  • 目標疾病的盛行率
  • 法律規範
  • 報銷框架
• 中西部
  • 主要地區趨勢
  • 目標疾病的盛行率
  • 法律規範
  • 報銷框架
• 東北
  • 主要地區趨勢
  • 目標疾病的盛行率
  • 法律規範
  • 報銷框架
• 西南
  • 主要地區趨勢
  • 目標疾病的盛行率
  • 法律規範
  • 報銷框架
• 東南
  • 主要地區趨勢
  • 目標疾病的盛行率
  • 法律規範
  • 報銷框架

第9章 競爭態勢

• 參與者概覽
• 企業市場分析
• 公司分類
• 戰略地圖
• 公司簡介/上市公司
  • Biogen
  • Novartis AG
  • Eli Lilly and Company
  • UCB SA
  • Merck &Co., Inc.
  • Johnson &Johnson Services, Inc.

U.S. Inflammatory Bowel Disease Treatment Market Growth & Trends:

The U.S. inflammatory bowel disease treatment market size is anticipated to reach USD 15.70 billion by 2030 and is projected to grow at a CAGR of 2.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of ulcerative colitis and Crohn's disease across the U.S. is anticipated to drive market growth in the forecast period. A combination of genetic predisposition, immune system dysfunction, environmental factors, gut microbiota imbalance, and lifestyle factors likely influence the development of inflammatory bowel disease (IBD). According to an article published in 2023, inflammatory bowel disease is a relatively common chronic condition affecting >0.7% of Americans and is most prevalent in the Northeastern region. This growing patient population necessitates advanced treatment options, driving the market growth.

The Crohn's & Colitis Foundation works toward enhancing product development to improve the quality of life of patients suffering from inflammatory bowel illnesses. The foundation has launched these ventures, a dedicated funding system to support product-oriented research and development.

In September 2023, Takeda announced the FDA's acceptance of the biologics license application (BLA) for the subcutaneous administration of ENTYVIO (vedolizumab) to treat Crohn's disease. Regulatory approvals pave the way for new medications, biologics, and devices to enter the market. This can lead to a broader range of treatment options for patients with IBD, potentially improving treatment outcomes and quality of life.

U.S. Inflammatory Bowel Disease Treatment Market Report Highlights:

• Based on type, the Crohn's disease segment dominated the market in 2024 with the largest revenue share. This large share is due to the requirement for more treatment options and advancements due to the chronic inflammatory nature of Crohn's disease, which affects the gastrointestinal tract and causes symptoms such as abdominal pain, diarrhea, weight loss, and fatigue.
• Based on drug class, the TNF inhibitors segment accounted for the largest market revenue share in 2024 due to their effectiveness in managing the symptoms and reducing inflammation.
• Based on route of administration, the injectable segment held the largest market share in 2024. Injectable medications, such as biologics and biosimilars, are designed to target specific proteins or cells involved in the inflammatory process of inflammatory bowel disease.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Drug Class
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Inflammatory Bowel Disease Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
    • 3.3.3.1. Phase 1
    • 3.3.3.2. Phase 2
    • 3.3.3.3. Phase 3
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. U.S. Inflammatory Bowel Disease Treatment market: Type Business Analysis

• 4.1. Type Market Share, 2024 & 2030
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Crohn's Disease
  • 4.4.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
• 4.5. Ulcerative Colitis
  • 4.5.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Inflammatory Bowel Disease Treatment market: Drug Class Business Analysis

• 5.1. Drug Class Market Share, 2024 & 2030
• 5.2. Drug Class Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 5.4. Aminosalicylates
  • 5.4.1. Aminosalicylates Market, 2018 - 2030 (USD Million)
• 5.5. Corticosteroids
  • 5.5.1. Corticosteroids Market, 2018 - 2030 (USD Million)
• 5.6. TNF Inhibitors
  • 5.6.1. TNF Inhibitors Market, 2018 - 2030 (USD Million)
• 5.7. IL inhibitors
  • 5.7.1. IL inhibitors Market, 2018 - 2030 (USD Million)
• 5.8. Anti-integrin
  • 5.8.1. Anti-integrinMarket, 2018 - 2030 (USD Million)
• 5.9. JAK inhibitors
  • 5.9.1. JAK inhibitors Market, 2018 - 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Inflammatory Bowel Disease Treatment market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2024 & 2030
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Oral
  • 6.4.1. Oral Market, 2018 - 2030 (USD Million)
• 6.5. Injectable
  • 6.5.1. Injectable Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Inflammatory Bowel Disease Treatment market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2024 & 2030
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 7.4. Hospital Pharmacy
  • 7.4.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
• 7.5. Retail Pharmacy
  • 7.5.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
• 7.6. Online Pharmacy
  • 7.6.1. Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 8. U.S. Inflammatory Bowel Disease Treatment market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
• 8.4. West.
  • 8.4.1. Key Country Dynamics
  • 8.4.2. Target Disease Prevalence
  • 8.4.3. Regulatory Framework
  • 8.4.4. Reimbursement Framework
  • 8.4.5. West U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Midwest
  • 8.5.1. Key Country Dynamics
  • 8.5.2. Target Disease Prevalence
  • 8.5.3. Regulatory Framework
  • 8.5.4. Reimbursement Framework
  • 8.5.5. Midwest U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Northeast
  • 8.6.1. Key Country Dynamics
  • 8.6.2. Target Disease Prevalence
  • 8.6.3. Regulatory Framework
  • 8.6.4. Reimbursement Framework
  • 8.6.5. Northeast U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Southwest
  • 8.7.1. Key Country Dynamics
  • 8.7.2. Target Disease Prevalence
  • 8.7.3. Regulatory Framework
  • 8.7.4. Reimbursement Framework
  • 8.7.5. Southwest U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. Southeast
  • 8.8.1. Key Country Dynamics
  • 8.8.2. Target Disease Prevalence
  • 8.8.3. Regulatory Framework
  • 8.8.4. Reimbursement Framework
  • 8.8.5. Southeast U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Biogen
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Novartis AG
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Eli Lilly and Company
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. UCB S.A.
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Merck & Co., Inc.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Johnson & Johnson Services, Inc.
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviation
• Table 3 U.S. inflammatory bowel disease market revenue estimates and forecast by type, 2018 - 2030 (USD Million)
• Table 4 Prevalence of Crohn's Disease in the U.S. (Per 100,000)
• Table 5 Prevalence of Ulcerative Colitis in the U.S. (Per 100,000)
• Table 6 U.S. inflammatory bowel disease market revenue estimates and forecast, by drug class, 2018 - 2030 (USD Million)
• Table 7 Key corticosteroid drugs used in the U.S. for IBD treatment
• Table 8 Key drugs with their description included in others segment
• Table 9 U.S. inflammatory bowel disease market revenue estimates and forecast, by route of administration, 2018 - 2030 (USD Million)
• Table 10 Key oral medications approved for IBD
• Table 11 U.S. inflammatory bowel disease market revenue estimates and forecast by distribution channel, 2018 - 2030 (USD Million)
• Table 12 Key players undertaking mergers and acquisitions
• Table 13 Key players undertaking partnerships and collaborations
• Table 14 Key players undertaking new product launches
• Table 15 Other strategies taken up by the market players

List of Figures

• Fig. 1 U.S. inflammatory bowel disease market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Type and drug class segment snapshot
• Fig. 11 Route of administration and distribution channel segment snapshot
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Parent market value, 2024 (USD billion)
• Fig. 14 Market dynamics
• Fig. 15 Porter's five forces analysis
• Fig. 16 PESTEL analysis
• Fig. 17 U.S. Inflammatory bowel disease market: Type outlook and key takeaways
• Fig. 18 U.S. Inflammatory Bowel Disease market: Type movement analysis
• Fig. 19 Crohn's disease market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Ulcerative colitis market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 U.S. inflammatory bowel disease market: Drug class outlook and key takeaways
• Fig. 22 U.S. inflammatory bowel disease market: Drug class movement analysis
• Fig. 23 Aminosalicylates market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 TNF inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 IL inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Anti-integrin market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 JAK inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 U.S. inflammatory bowel disease market: Route of administration outlook and key takeaways
• Fig. 31 U.S. inflammatory bowel disease market: Route of administration movement analysis
• Fig. 32 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 U.S. inflammatory bowel disease market: Distribution channel outlook and key takeaways
• Fig. 35 U.S. inflammatory bowel disease market: Distribution channel movement analysis
• Fig. 36 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Market participant categorization
• Fig. 40 Company heat map analysis
• Fig. 41 Strategic framework